Claims for Patent: 11,065,265

Summary for Patent: 11,065,265

Title:	Compositions of fosaprepitant and methods of preparation
Abstract:	The present application and its embodiments teach stable compositions of fosaprepitant or a pharmaceutically acceptable salt thereof with such compositions lacking polysorbate 80 and containing dual functional excipients of hydrolysis inhibition and solubility enhancement. Further described are methods of preparation of such compositions. Among other advantages of contemplated compositions, fosaprepitant hydrolysis degradation is kept low and the compositions maintain physically and chemically stable for prolonged period.
Inventor(s):	Yu Jianwei, Wang Yulu
Assignee:	SPES PHARMACEUTICALS INC.
Application Number:	US16245992
Patent Claims:	1. A stable , liquid composition comprising:fosaprepitant or a pharmaceutically acceptable salt thereof;at least one pharmaceutically acceptable derivative of β-cyclodextrin;a pharmaceutically acceptable carrier;a pH adjusting agent;wherein the composition does not contain polysorbate 80;wherein a weight ratio of the fosaprepitant or a pharmaceutically acceptable salt thereof to the at least one pharmaceutically acceptable derivative of β-cyclodextrin is about 1:10 to about 1:255; andwherein a stability of the stable, liquid composition is maintained for at least three months at 25° C.2. The composition of further comprising at least one pharmaceutical additive.3. The composition of wherein a pH of the composition is adjusted to about 9 to about 11.4. The composition of wherein the fosaprepitant is fosaprepitant dimeglumine.5. The composition of wherein the fosaprepitant dimeglumine is present in an amount of about 1.6 mg/mL to about 9.8 mg/mL.6. The composition of wherein the at least one pharmaceutically acceptable derivative of β-cyclodextrin is a sulfobutyl ether β-cyclodextrin sodium salt.7. The composition of wherein the composition is physically and chemically stable for at least three months at 25° C.8. The composition of wherein after three months the total degradation products of the composition are about less than 1.0% (w/w).9. The composition of wherein the total degradation products comprises aprepitant.10. A stable anti-emetic composition suitable for parenteral injection claim 8 , the composition comprising:about 1.6 mg/mL to about 9.8 mg/mL of fosaprepitant or a pharmaceutically acceptable salt thereof;about 63 mg/mL to about 256 mg/mL of at least one pharmaceutically acceptable derivative of β-cyclodextrin;a pharmaceutically acceptable carrier; anda pH adjusting agent,wherein a pH of the composition is adjusted to about 9 to about 12;wherein the composition does not contain polysorbate 80;wherein a weight ratio of the fosaprepitant or a pharmaceutically acceptable salt thereof to the at least one pharmaceutically acceptable derivative of β-cyclodextrin is about 1:20 to about 1:85; andwherein a stability of the composition is maintained for at least three months at 25° C.11. The composition of wherein the pH adjusting agent is NaOH or HCl.12. The composition of wherein the pH is more preferably adjusted to about 9 to about 11.13. The composition of wherein after three months at 25° C. the composition contains less than 0.8% (w/w) of aprepitant.14. The composition of further comprising at least one chelating agent.15. The composition of wherein the at least one chelating agent is aminopolycarboxylic acid or salt thereof.16. A method of preparing a stable anti-emetic composition suitable for parenteral injection according to claim 1 , the method comprising the steps of:dissolving fosaprepitant or a pharmaceutically acceptable salt thereof in water forming a solution;adding a cyclodextrin derivative to the solution;dissolving the cyclodextrin derivative in the solution forming a clear solution;adding other pharmaceutically acceptable excipients;adjusting a pH of the clear solution; andadding water to the clear solution to bring the clear solution to a final volume.17. A stable anti-emetic composition suitable for parenteral injection claim 1 , the composition comprising:about 1.6 mg/mL to about 9.8 mg/mL of fosaprepitant dimeglumine;about 63 mg/mL to about 256 mg/mL of sulfobutyl ether β-cyclodextrin;no more than about 0.4 mg/mL of edetate disodium;a pharmaceutically acceptable carrier; and 'wherein the pH of the solution is adjusted to about 10 to about 11;', 'a pH adjusting agent,'}wherein the composition does not contain polysorbate 80;wherein a weight ratio of the fosaprepitant dimeglumine to the sulfobutyl ether β-cyclodextrin is about 1:20 to about 1:85; andwherein a stability of the composition is maintained for at least three months at 25° C.18. The composition of wherein the stability of the composition is both a physical and chemical stability.19. The composition of wherein the pharmaceutically acceptable carrier is an aqueous solution comprising at least 80% water.